$2.32
0.43% yesterday
Nasdaq, Sep 22, 10:00 pm CET
ISIN
US28658R1068
Symbol
CLYM

Eliem Therapeutics Inc Stock price

$2.32
-0.06 2.52% 1M
+1.00 75.76% 6M
+0.52 28.89% YTD
-5.31 69.59% 1Y
-1.12 32.56% 3Y
-13.58 85.41% 5Y
-13.58 85.41% 10Y
-13.58 85.41% 20Y
Nasdaq, Closing price Mon, Sep 22 2025
+0.01 0.43%
ISIN
US28658R1068
Symbol
CLYM
Industry

Key metrics

Basic
Market capitalization
$156.5m
Enterprise Value
$71.8m
Net debt
positive
Cash
$84.7m
Shares outstanding
67.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
97.6%
Return on Equity
-34.9%
ROCE
-28.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-52.9m | -
EBIT
$-53.0m | $-59.7m
Net Income
$-46.8m | $-51.3m
Free Cash Flow
$-39.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-240.7% | -121.3%
Net Income
27.2% | 30.6%
Free Cash Flow
-765.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.7
FCF per Share
$-0.6
Short interest
3.3%
Employees
-
Rev per Employee
-
Show more

Is Eliem Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Eliem Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Eliem Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Eliem Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Eliem Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
108% 108%
-
- Research and Development Expense 33 33
444% 444%
-
-53 -53
-
-
- Depreciation and Amortization 0.04 0.04
-
-
EBIT (Operating Income) EBIT -53 -53
241% 241%
-
Net Profit -47 -47
27% 27%
-

In millions USD.

Don't miss a Thing! We will send you all news about Eliem Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eliem Therapeutics Inc Stock News

Neutral
GlobeNewsWire
19 days ago
WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the CLYM116 webcast event, which is set for Monday, September 29, 2025, at 8:00 a.m.
Neutral
GlobeNewsWire
28 days ago
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below.
Neutral
GlobeNewsWire
29 days ago
WELLESLEY HILLS, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that members of its executive team will participate in the upcoming investor conferences detailed below.
More Eliem Therapeutics Inc News

Company Profile

Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy. ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator (PAM) initially being developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Redmond, WA.

Head office United States
CEO Aoife Brennan
Founded 2018
Website climbbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today